Trials / Completed
CompletedNCT00477529
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Celgene · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
Detailed description
Detailed description not necessary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-008 | nab-docetaxel |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2011-06-02
- Completion
- 2011-06-02
- First posted
- 2007-05-23
- Last updated
- 2019-11-22
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00477529. Inclusion in this directory is not an endorsement.